| 潘 彬,马秀芬,王燕侠,独小燕,隆建萍,毛红岩.脾多肽联合化疗对乳腺癌患者T淋巴细胞亚群、生活质量及血清肿瘤标志物的影响[J].,2020,(11):2122-2125 |
| 脾多肽联合化疗对乳腺癌患者T淋巴细胞亚群、生活质量及血清肿瘤标志物的影响 |
| Effects of Splenic Polypeptide Combined with Chemotherapy on T Lymphocyte Subsets, Quality of Life and Serum Tumor Markers in Patients with Breast Cancer |
| 投稿时间：2019-10-05 修订日期：2019-10-30 |
| DOI：10.13241/j.cnki.pmb.2020.11.026 |
| 中文关键词: 脾多肽 化疗 乳腺癌 T淋巴细胞亚群 生活质量 肿瘤标志物 |
| 英文关键词: Spleen polypeptide Chemotherapy Breast cancer T lymphocyte subsets Quality of life Tumor markers |
| 基金项目:甘肃省卫生行业科研计划项目（GSWSKY20161021） |
|
| 摘要点击次数: 835 |
| 全文下载次数: 455 |
| 中文摘要: |
| 摘要 目的：探讨脾多肽联合化疗治疗乳腺癌患者的临床疗效。方法：选取我院于2015年2月~2019年2月期间收治的93例乳腺癌患者，根据乱数表法将患者分为研究组（n=47，脾多肽联合化疗）、对照组（n=46，常规化疗），比较两组临床疗效、T淋巴细胞亚群、生活质量、血清肿瘤标志物、不良反应。结果：研究组治疗4个周期后的临床总有效率为78.72%（37/47），显著高于对照组的56.52%（26/46）（P<0.05）。研究组治疗4个周期后CD3+、CD4+、CD4+/CD8+以及情感功能、躯体功能、总体健康、精神状态评分高于对照组，CD8+则低于对照组（P<0.05）。研究组治疗4个周期后血清糖类抗原153（CA153）、肿瘤特异性生长因子（TSGF）、组织多肽特异性抗原（TPS）水平低于对照组（P<0.05）。两组患者不良反应发生率比较无差异（P>0.05）。结论：脾多肽联合化疗治疗乳腺癌患者的疗效显著，可有效改善其T淋巴细胞亚群、生活质量及血清肿瘤标志物水平，用药安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of splenic polypeptide combined with chemotherapy on T lymphocyte subsets, quality of life and serum tumor markers in patients with breast cancer. Methods: 93 patients with breast cancer who were admitted to our hospital from February 2015 to February 2019 were selected, and they were divided into study group (n=47, spleen polypeptide combined chemotherapy) and control group (n=46, routine chemotherapy) according to random number table method. The clinical efficacy, T lymphocyte subsets, quality of life, serum tumor markers and adverse reactions were compared between two groups. Results: The total effective rate of the study group was 78.72% (37/47) at 4 cycles after treatment, which was significantly higher than that of the control group 56.52% (26/46)(P<0.05). At 4 cycles after treatment, the levels of CD3+, CD4+, CD4+/CD8+, the scores of emotional function, physical function, general health and mental state in the study group were higher than those in the control group, while the levels of CD8+ in the study group was lower than that in the control group(P<0.05). The levels of serum Carbohydrate antigen 153(CA153), tumor specific growth factor (TSGF), tissue polypeptide specific antigen (TPS) in the study group were lower than those in the control group at 4 cycles after treatment(P<0.05). There was no difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Spleen polypeptide combined with chemotherapy is effective in the treatment of breast cancer. It can effectively improve T lymphocyte subsets, quality of life and serum tumor markers. It has good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
